Rakesh Jain

Dr. Rakesh Jain is a pioneer in tumor vascular biology who proposed the vascular normalization hypothesis: that low-dose anti-VEGF therapy transiently normalizes abnormal tumor vessels, reducing tumor hypoxia and improving drug delivery within a normalization window. He has shown that vascular normalization can enhance immunotherapy by enabling immune cell infiltration and oxygenating the tumor microenvironment. His translational research connects anti-angiogenic therapy mechanisms with optimized combination strategies.